SAN DIEGO, Oct. 6 Biocept, Inc. ("Biocept"), an emergingleader in biotechnology, announced today the appointment of Stephen M. Coutts,Ph.D. as CEO, President and Director and the appointment of Edward A. Dennis,Ph.D., as Director. Biocept also announced the resignation of its former CEO,President and Director, Gordon F. Janko.
"We are pleased to welcome Dr. Coutts, a highly regarded professional inour field, and believe he is a good fit with our development strategy," saidClaire K.T. Reiss, Chairman of the Board. "In addition, we are honored to addDr. Dennis to the Board and look forward to benefiting from his extensiveexperience and perspective. On behalf of the Biocept Board of Directors, Iwould also like to thank Mr. Janko for his contributions during the five yearsthat he led Biocept," Ms. Reiss added.
"I am delighted to join Biocept at this critical time and look forward tocontinuing to develop and grow this exciting technology," said Dr. Coutts.
Dr. Coutts has 30 years of experience in the pharmaceutical andbiotechnical industries. He was most recently Director of PharmaceuticalDevelopment at Cypress Bioscience, Inc. and a principal at Alembic BiotechConsultants. He was previously President and COO at Triad Therapeutics, Inc.and spent 11 years as Executive Vice President for R&D at La JollaPharmaceutical. Dr. Coutts holds a BS in Chemistry from San Diego StateUniversity, a Ph.D. in Biochemistry from Harvard University and an MBA fromNew York University.
Dr. Dennis is Distinguished Professor of Chemistry and Biochemistry and ofPharmacology in the School of Medicine at the University of California at SanDiego (UCSD). He is currently Editor-in-Chief of the Journal of Lipid Researchand has been named a Fellow of the American Association for the Advancement ofSciences. Dr. Dennis serves on the Scientific Advisory Board and Board ofDirectors of several private and public companies. He received his BA fromYale University and a Ph.D. from Harvard University.
Biocept, an emerging biotechnology leader, engineers novel microfluidicdevices that provide the foundation for a new class of diagnostic assays.Biocept is based in San Diego, California, a major center for academic andindustrial life sciences research. Founded in 1997, the company is privatelyheld and draws on a team rich in experience in life science. Its CLIA clinicallaboratory is accredited by the College of American Pathologists and holdslicenses in California and other states as required.
SOURCE Biocept, Inc.